The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
 
Ana Christina Garrido-Castro
No Relationships to Disclose
 
Tanya Elizabeth Keenan
Employment - 5AM Ventures (I)
Stock and Other Ownership Interests - Aeglea Biotherapeutics (I); Alnylam (I); Crinetics Pharmaceuticals (I); Trillium Therapeutics (I)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel; Merck (Inst)
 
Tianyu Li
No Relationships to Disclose
 
Paulina Lange
No Relationships to Disclose
 
Catherine Callahan
No Relationships to Disclose
 
Jennifer Guerriero
Consulting or Advisory Role - Array BioPharma; Codagenix; GlaxoSmithKline; Verseau Therapeutics
Research Funding - Array BioPharma/Pfizer; GlaxoSmithKline; Lilly
 
Nabihah Tayob
No Relationships to Disclose
 
Leilani Anderson
No Relationships to Disclose
 
Clinton Yam
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Merck (Inst)
 
Brooke R. Daniel
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - Abbvie (Inst); Immunomedics (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; Immunomedics; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Eric P. Winer
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Athenex; Carrick Therapeutics; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen; Syros Pharmaceuticals; Zymeworks
Research Funding - Genentech (Inst)
Other Relationship - InfiniteMD
 
Elizabeth A. Mittendorf
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Exact Sciences; Merck; Roche; Roche/Genentech
Research Funding - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Lilly
 
Sara M. Tolaney
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bristol-Myers Squibb; Celldex; Certara Inc; CytomX Therapeutics; Daiichi Sankyo; Eisai; G1 Therapeutics; Genentech; Immunomedics/Gilead; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; Paxman; Pfizer; Puma Biotechnology; Samsung Bioepis; Sanofi; Seagen; Silverback Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology